Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03856658 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 2025 to Dec 2028
    • Study site revised
    v12
  2. Primary and study completion dates: Dec 2027 to Dec 2025v11
  3. Primary and study completion dates: Dec 2026 to Dec 2027
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 15 to confirmed 14
    • Site details revised
    v10
  4. Primary and study completion dates: Apr 2026 to Dec 2026v9
  5. Primary and study completion dates: Apr 2024 to Apr 2026v8
Show 6 earlier versionsHide 6 earlier versions
  1. 2 versions Re-verified since May 31, 2023, no change to tracked fieldsv6-v7
  2. Site contact updatedv5
  3. Primary completion date: Apr 2022 to Apr 2024
    • Study completion date: Apr 2023 to Apr 2024
    v4
  4. Primary completion date: Apr 2020 to Apr 2022
    • Study completion date: Apr 2021 to Apr 2023
    v3
  5. Interventions: FUDR via HAI pump (Combination Product) to Floxuridine (FUDR) (Drug), Heparinized Saline (Drug), Hepatic Artery Infusion Pump (Device)v2 Show 4 more changesShow less
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints revised (4)
    • Site contact updated
    • Study description expanded, about 2 words
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single arm, phase II study without blinding. The purpose is to determine the impact of hepatic artery infusion Floxuridine (FUDR) on liver metastases from pancreatic adenocarcinoma. Patients at Spectrum Health will receive standard of care chemotherapy. They will also receive chemotherapy via surgically placed hepatic artery infusion (HAI) pump.
Trial Details
NCT Number NCT03856658
Lead Sponsor Corewell Health West
Conditions
(from sponsor)		 Pancreatic Adenocarcinoma, Liver Metastases
Related terms Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms
Enrollment 14 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov